KALV KalVista Pharmaceuticals Inc.

19.25
-0.27  -1%
Previous Close 19.52
Open 19.71
52 Week Low 12.01
52 Week High 45
Market Cap $470,428,921
Shares 24,437,866
Float 22,307,697
Enterprise Value $253,775,144
Volume 893,827
Av. Daily Volume 165,927
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
KVD824 (KOMPLETE)
Hereditary angioedema
Phase 2
Phase 2
Phase 2 clinical hold removed by FDA September 14, 2021. Regulatory submissions approved in Canada, Australia, and the UK with patient enrollment underway September 9, 2021.
KVD900
Hereditary Angioedema (HAE)
Phase 2
Phase 2
Phase 2 positive data released February 9, 2021. Significantly reduced use of rescue (p=0.001), with 15% of KVD900 treated attacks rescued compared to 30% on placebo at 12 hours. FDA End-of-Phase 2 Meeting scheduled for September 2021. Received orphan drug designation by FDA.
KVD001
Diabetic macular edema (DME)
Phase 2
Phase 2
Phase 2 data did not meet primary endpoint - December 9, 2019.

Latest News

  1. – US Site Initiations Ongoing –

    – Regulatory Submissions Complete for All Countries Participating in Trial –

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's Phase 2 clinical trial of KVD824 for oral prophylactic treatment of hereditary angioedema (HAE).

    "The execution of KOMPLETE, our Phase 2 clinical trial for KVD824 as a potential oral prophylactic therapy for HAE, is expected to accelerate now that we can also proceed at our U.S. trial sites," said Andrew Crockett, Chief Executive Officer of…

    – US Site Initiations Ongoing –

    – Regulatory Submissions Complete for All Countries Participating in Trial –

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's Phase 2 clinical trial of KVD824 for oral prophylactic treatment of hereditary angioedema (HAE).

    "The execution of KOMPLETE, our Phase 2 clinical trial for KVD824 as a potential oral prophylactic therapy for HAE, is expected to accelerate now that we can also proceed at our U.S. trial sites," said Andrew Crockett, Chief Executive Officer of KalVista. "Progress continues worldwide, with regulatory submissions complete in all of the countries where the trial will be conducted."

    The previously announced clinical hold was removed after FDA review of KalVista's responses to the FDA request for further information and analysis related to certain preclinical studies of KVD824. Refinements were also made to the KVD824 Phase 2 KOMPLETE protocol. The Company is working closely with study investigators and clinical trial sites to proceed with all study activities as soon as possible.

    KalVista has previously reported data from first-in-human and formulation studies of KVD824 that were conducted in the UK. To date, a total of 121 subjects have received KVD824 as single doses up to 1280 mg and up to 14 days of twice-daily dosing of 600 mg and 900 mg. Data from the Phase 1 studies indicate that KVD824 maintains the plasma concentrations that we believe are required to deliver efficacy consistent with approved injectable therapies. In both studies adverse event rates were similar in placebo and active arms, no subjects withdrew, and no serious adverse events were reported.

    About KVD824 KOMPLETE Clinical Trial

    KOMPLETE is the Phase 2 clinical trial of KVD824, and is a randomized, double-blind, parallel group design evaluating twice-daily dosing of 300 mg, 600 mg, and 900 mg KVD824 against placebo for 12 weeks. The trial is intended to enroll 48 HAE patients randomized into four equal arms after they report experiencing a minimum of three attacks in an eight-week run-in period. The primary endpoint of the trial is the rate of investigator confirmed HAE attacks during the treatment period. Secondary endpoints include the proportion of participants without investigator confirmed HAE attacks and the rate of investigator confirmed HAE attacks that require conventional treatment. KOMPLETE will be conducted at more than 30 sites in 13 countries.

    About KalVista Pharmaceuticals, Inc.

    KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista's oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

    For more information, please visit www.kalvista.com.

    Forward-Looking Statements

    This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 2 KOMPLETE clinical trial, and to obtain regulatory approvals for KVD900, KVD824 and other candidates in development, the ability of KVD900, KVD824 and other candidates in development to treat HAE or DME, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2021, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    View Full Article Hide Full Article
  2. – FDA End-of-Phase 2 Meeting for KVD900 Oral HAE Phase 3 Program Scheduled for This Month –

    – KVD824 Phase 2 KOMPLETE Clinical Trial Enrolling –

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2021.

    "We have made excellent progress in the rollout of our Phase 2 KOMPLETE clinical trial for KVD824," said Andrew Crockett, Chief Executive Officer of KalVista. "Site initiations are underway, and patients are being enrolled in the trial to evaluate KVD824 as a potential oral prophylactic treatment…

    – FDA End-of-Phase 2 Meeting for KVD900 Oral HAE Phase 3 Program Scheduled for This Month –

    – KVD824 Phase 2 KOMPLETE Clinical Trial Enrolling –

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2021.

    "We have made excellent progress in the rollout of our Phase 2 KOMPLETE clinical trial for KVD824," said Andrew Crockett, Chief Executive Officer of KalVista. "Site initiations are underway, and patients are being enrolled in the trial to evaluate KVD824 as a potential oral prophylactic treatment for HAE. We will be having an end-of-Phase 2 meeting with the FDA later this month regarding KVD900, our oral on-demand candidate for treatment of HAE attacks and are ready to initiate the Phase 3 study quickly afterwards. We look forward to advancing both of these compounds as we continue with our strategy of bringing a full spectrum of oral treatment options to HAE patients."

    First Fiscal Quarter and Recent Business Highlights:

    • Presented Phase 2 data for KVD900 in late-breaking session at European Academy of Allergy and Clinical Immunology (EAACI) Congress. The data showed that a single on-demand treatment with orally administered KVD900 significantly slows progression and accelerates resolution of attacks in patients with hereditary angioedema (HAE). KalVista also presented four other posters at EAACI related to the HAE clinical landscape and unmet needs, as well as preclinical data from other oral molecules.
    • Scheduled an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to review the proposed development plans for KVD900, KalVista's oral on-demand candidate for treatment of HAE attacks, expected to take place in September 2021. KVD900 also received Orphan Drug Designation from the FDA.
    • Presented data at the International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress showcasing small molecule Factor XIIa inhibitor research.
    • Provided a progress update on the KVD824 Phase 2 KOMPLETE Clinical Trial. KVD824 is in development for oral prophylactic treatment of HAE. Regulatory submissions have been approved in Canada, Australia, and the UK with patient enrollment now underway. KalVista also submitted a response to the clinical hold related to the U.S. Investigational New Drug (IND) filing for KVD824 and is prepared to initiate the study in the U.S. upon clearance from the FDA.
    • Presented KVD001 data at American Chemical Society (ACS) Meeting.

    First Fiscal Quarter Financial Results:

    • Revenue: No revenue was recognized for the three months ended July 31, 2021 or July 31, 2020.
    • R&D Expenses: Research and development expenses were $13.7 million for the three months ended July 31, 2021, compared to $11.2 million for the same period in the prior fiscal year. The increase in R&D expenses during the quarter primarily reflects increased preclinical spending and the ongoing clinical trial for KVD824, offset by a decrease in spending on KVD900 and KVD001 due to their concluded Phase 2 clinical trials in February 2021 and December 2019, respectively.
    • G&A Expenses: General and administrative expenses were $5.9 million for the three months ended July 31, 2021, compared to $3.3 million for the same period in the prior fiscal year. The increase in G&A expenses was primarily due to an increase in compensation related expenses and to a lesser extent, increases in commercial planning expenses, professional fees, and other administrative costs.
    • Net Loss: Net loss was $16.1 million, or $(0.66) per weighted average basic and diluted share, for the three months ended July 31, 2021, compared to net loss of $10.8 million, or $(0.61) per weighted average basic and diluted share for the same period in the prior fiscal year. The increase in net loss and net loss per share primarily resulted from the increase in operating expenses, primarily research and development.
    • Cash Position: Cash, cash equivalents and marketable securities were $230.6 million as of July 31, 2021, compared to $248.9 million as of April 30, 2021. The decrease in the net cash position was due to increased operating expenses.

    About KalVista Pharmaceuticals, Inc.

    KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista's oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

    For more information, please visit www.kalvista.com.

    Forward-Looking Statements

    This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence or complete clinical studies, including our Phase 2 KOMPLETE clinical trial, and to obtain regulatory approvals for KVD900, KVD824 and other candidates in development, our ability to resolve a clinical hold with regards to KVD824, the ability of KVD900, KVD824 and other candidates in development to treat HAE or DME, the future progress and potential success of our oral Factor XIIa program, and the sufficiency of our cash, cash equivalents and investments to fund our operations. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2021, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    KalVista Pharmaceuticals Inc.
    Condensed Consolidated Balance Sheets
    (in thousands, except share and per share amounts)
    (Unaudited)
     

    July 31,

     

    April 30,

    2021

     

    2021

    Assets
    Current assets:
    Cash and cash equivalents

    $

    48,343

     

    $

    50,592

     

    Marketable securities

     

    182,288

     

     

    198,337

     

    Research and development tax credit receivable

     

    13,613

     

     

    10,418

     

    Prepaid expenses and other current assets

     

    5,538

     

     

    4,917

     

    Total current assets

     

    249,782

     

     

    264,264

     

    Property and equipment, net

     

    1,944

     

     

    1,791

     

    Right of use assets

     

    7,207

     

     

    5,758

     

    Other assets

     

    200

     

     

    200

     

    Total assets

    $

    259,133

     

    $

    272,013

     

    Liabilities and stockholders' equity
    Current liabilities:
    Accounts payable

    $

    1,448

     

    $

    1,981

     

    Accrued expenses

     

    5,876

     

     

    6,930

     

    Lease liability - current portion

     

    905

     

     

    863

     

    Total current liabilities

     

    8,229

     

     

    9,774

     

    Long-term liabilities:
    Lease liability - net of current portion

     

    6,474

     

     

    5,046

     

    Total long-term liabilities

     

    6,474

     

     

    5,046

     

    Stockholders' equity:
    Common stock, $0.001 par value

     

    24

     

     

    24

     

    Additional paid-in capital

     

    429,840

     

     

    426,437

     

    Accumulated deficit

     

    (183,945

    )

     

    (167,836

    )

    Accumulated other comprehensive loss

     

    (1,489

    )

     

    (1,432

    )

    Total stockholders' equity

     

    244,430

     

     

    257,193

     

    Total liabilities and stockholders' equity

    $

    259,133

     

    $

    272,013

     

     
    KalVista Pharmaceuticals Inc.
    Condensed Consolidated Statement of Operations
    (in thousands, except share and per share amounts)
    (Unaudited)
     
     

    Three Months Ended

    July 31,

    2021

     

    2020

     
    Revenue

    $

     

    $

     

    Operating expenses:
    Research and development

     

    13,669

     

     

    11,165

     

    General and administrative

     

    5,847

     

     

    3,278

     

    Total operating expenses

     

    19,516

     

     

    14,443

     

    Operating loss

     

    (19,516

    )

     

    (14,443

    )

     
    Other income:
    Interest income

     

    274

     

     

    259

     

    Foreign currency exchange rate (loss) gain

     

    (51

    )

     

    438

     

    Other income

     

    3,184

     

     

    2,932

     

    Total other income

     

    3,407

     

     

    3,629

     

    Net loss

    $

    (16,109

    )

    $

    (10,814

    )

     
    Net loss per share, basic and diluted

    $

    (0.66

    )

    $

    (0.61

    )

     
    Weighted average common shares outstanding, basic and diluted

     

    24,429,919

     

     

    17,848,583

     

     
    KalVista Pharmaceuticals Inc.
    Condensed Consolidated Statements of Cash Flows
    (in thousands, unaudited)
     

    Three Months Ended

    July 31,

    2021

     

    2020

     
    Cash flows from operating activities
    Net loss

    $

    (16,109

    )

    $

    (10,814

    )

    Adjustments to reconcile net loss to net cash used in operating activities:
    Depreciation and amortization

     

    132

     

     

    128

     

    Stock-based compensation expense

     

    2,795

     

     

    1,188

     

    Realized loss (gain) from sale of marketable securities

     

    23

     

     

    (70

    )

    Non-cash operating lease expense

     

    22

     

     

    8

     

    Amortization of premium on marketable securities

     

    753

     

     

    68

     

    Foreign currency exchange loss (gain)

     

    14

     

     

    (432

    )

    Changes in operating assets and liabilities:
    Research and development tax credit receivable

     

    (3,211

    )

     

    4,462

     

    Prepaid expenses and other current assets

     

    (625

    )

     

    1,301

     

    Accounts payable

     

    (528

    )

     

    35

     

    Accrued expenses

     

    (1,001

    )

     

    538

     

    Net cash used in operating activities

     

    (17,735

    )

     

    (3,588

    )

     
    Cash flows from investing activities
    Purchases of marketable securities

     

    (19,036

    )

     

    (9,807

    )

    Sales and maturities of marketable securities

     

    34,204

     

     

    15,342

     

    Acquisition of property and equipment

     

    (287

    )

     

    (22

    )

    Net cash provided by investing activities

     

    14,881

     

     

    5,513

     

     
    Cash flows from financing activities
    Issuance of common stock from equity incentive plans

     

    608

     

     

    46

     

    Net cash provided by financing activities

     

    608

     

     

    46

     

    Effect of exchange rate changes on cash and cash equivalents

     

    (3

    )

     

    254

     

    Net (decrease) increase in cash and cash equivalents

     

    (2,249

    )

     

    2,225

     

    Cash and cash equivalents at beginning of period

     

    50,592

     

     

    15,789

     

    Cash and cash equivalents at end of period

    $

    48,343

     

    $

    18,014

     

     

     

    View Full Article Hide Full Article
  3. KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on September 1, 2021 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

    The options have an exercise price of $20.76 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject…

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on September 1, 2021 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

    The options have an exercise price of $20.76 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista's Inducement Equity Incentive Plan and a stock option agreement covering the grant.

    About KalVista Pharmaceuticals, Inc.

    KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista's oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

    For more information, please visit www.kalvista.com.

    View Full Article Hide Full Article
  4. – KVD824 Clinical Trial Regulatory Approvals in Canada, Australia, and the UK –

    – Response Submitted to FDA on IND Requests for KVD824 Phase 2 –

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on clinical trial progress for KVD824 in development for oral prophylactic treatment of hereditary angioedema (HAE).

    "Over the past month we have made substantial progress in commencing KOMPLETE, our worldwide Phase 2 clinical trial of KVD824 as a potential oral prophylactic therapy for HAE," said Andrew Crockett, Chief Executive Officer of KalVista. "The regulatory submissions have been…

    – KVD824 Clinical Trial Regulatory Approvals in Canada, Australia, and the UK –

    – Response Submitted to FDA on IND Requests for KVD824 Phase 2 –

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on clinical trial progress for KVD824 in development for oral prophylactic treatment of hereditary angioedema (HAE).

    "Over the past month we have made substantial progress in commencing KOMPLETE, our worldwide Phase 2 clinical trial of KVD824 as a potential oral prophylactic therapy for HAE," said Andrew Crockett, Chief Executive Officer of KalVista. "The regulatory submissions have been approved in Canada, Australia, and the UK, with patient enrollment expected to begin this quarter. We also submitted our clinical hold response to the FDA related to the US IND filing for KVD824 and will provide further updates once we have additional information."

    KOMPLETE is the Phase 2 clinical trial of KVD824, and is a randomized, double-blind, parallel group design evaluating twice-daily dosing of 300 mg, 600 mg, and 900 mg KVD824 against placebo for 12 weeks. The trial will enroll 48 HAE patients randomized into four equal arms after they report experiencing a minimum of three attacks in an eight-week run-in period. The primary endpoint of the trial is the rate of investigator confirmed HAE attacks during the treatment period. Secondary endpoints include the proportion of participants without investigator confirmed HAE attacks and the rate of investigator confirmed HAE attacks that require conventional treatment. KOMPLETE will be conducted at more than 30 sites in 13 countries.

    To date, a total of 121 subjects have been exposed to treatment with KVD824 as single doses up to 1280 mg and up to 14 days of twice-daily dosing of 600 mg and 900 mg. The formulation of KVD824 maintains the plasma concentrations that we believe are required to deliver efficacy consistent with approved injectable therapies. Twice-daily dosing of KVD824 up to 14 days has demonstrated an encouraging safety and tolerability profile.

    About KalVista Pharmaceuticals, Inc.

    KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista's oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

    For more information, please visit www.kalvista.com.

    Forward-Looking Statements

    This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence or complete clinical studies, including our Phase 2 KOMPLETE clinical trial, and to obtain regulatory approvals for KVD900, KVD824 and other candidates in development, our ability to resolve a clinical hold with regards to KVD824, the ability of KVD900, KVD824 and other candidates in development to treat HAE or DME, the future progress and potential success of our oral Factor XIIa program, and the sufficiency of our cash, cash equivalents and investments to fund our operations. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2021, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    View Full Article Hide Full Article
  5. KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted four newly-hired employees inducement options to purchase an aggregate of 20,000 shares of KalVista common stock on August 3, 2021 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

    The options have an exercise price of $20.65 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject…

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted four newly-hired employees inducement options to purchase an aggregate of 20,000 shares of KalVista common stock on August 3, 2021 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

    The options have an exercise price of $20.65 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista's Inducement Equity Incentive Plan and a stock option agreement covering the grant.

    About KalVista Pharmaceuticals, Inc.

    KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE. In addition, KalVista's oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

    For more information, please visit www.kalvista.com.

    View Full Article Hide Full Article
View All KalVista Pharmaceuticals Inc. News